DIACEUTICS PLC

Director's Dealing • Sep 28, 2021

National Storage Mechanism | Additional information

RNS Number : 1376N

Diaceutics PLC

28 September 2021

28 September 2021

Diaceutics PLC

("Diaceutics" or "the Company")

Purchase and Transfer of Shares and PDMR Shareholdings

Diaceutics PLC, (AIM: DXRX), the diagnostic commercialisation company announces that on 27 September 2021, Deborah Davis, the Chair of Diaceutics, purchased 17,800 ordinary shares of £0.002 each in the Company ("Ordinary Shares") at a price of £1.11 pence per Ordinary Share.

In addition, Philip White transferred 150,000 Ordinary Shares to his father, Philip Michael White.

As a result of the purchase, Deborah's shareholding is 44,800 Ordinary Shares, representing approximately 0.05 % of the Company's issued share capital and as a result of Philip's transfer, the beneficial holding of Philip White will be 1,606,389 Ordinary Shares, representing 1.91 % of the Company's issued share capital.

Enquiries:

Diaceutics PLC
Philip White, Chief Financial Officer	Via Alma PR
Stifel Nicolaus Europe Limited (Nomad & Broker)	Tel: +44 (0)20 7710 7600
Ben Maddison
Stewart Wallace
Nick Adams
Alma PR	Tel: +44(0)20 3405 0205
Caroline Forde	diaceutics@almapr.co.uk
Robyn Fisher
Kieran Breheny

About Diaceutics

At Diaceutics we believe that every patient should have access to the right treatment at the right time. We provide the world's leading pharmaceutical companies with an end-to-end solution for the launch of precision medicine diagnostics enabled by DXRX - The Diagnostic Network®. 

DXRX is the world's first diagnostic commercialisation platform for precision medicine, integrating multiple pipelines of real-world diagnostic testing data from a global network of laboratories.

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1	Details of the person discharging managerial responsibilities/person closely associated
a.	Name	Deborah Davis
2	Reason for notification
a.	Position/Status	Chair
b.	Initial notification/ Amendment	Initial
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name	Diaceutics PLC
b.	LEI	213800VEWQBB39ZB8J81
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the financial instrument, type of instrument Identification Code	Ordinary shares of £0.002 each ISIN:  GB00BJQTGV64
b.	Nature of the transaction	Purchase
c.	Price(s) and volume(s)		Share purchase:
	Price(s)	Volume(s)
1.11	17,800
d.	Date of the transaction	27 September 2021
e.	Place of the transaction	AIM Market of the London Stock Exchange

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1	Details of the person discharging managerial responsibilities/person closely associated
a.	Name	Philip White
2	Reason for notification
a.	Position/Status	Chief Financial Officer
b.	Initial notification/ Amendment	Initial
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name	Diaceutics PLC
b.	LEI	213800VEWQBB39ZB8J81
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the financial instrument, type of instrument Identification Code	Ordinary shares of £0.002 ISIN:  GB00BJQTGV64
b.	Nature of the transaction	Transfer of ordinary shares for nil consideration to PDMR's father
c.	Price(s) and volume(s)
	Price(s)	Volume(s)
	Nil	150,000
e.	Date of the transaction	27 September 2021
f.	Place of the transaction	Outside a trading venue

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHFLFFAALIDFIL